Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection

Abstract

Rosuvastatin effectively lowers LDL and appears to substantially slow progression of CCA-IMT in patients with treated HIV infection. Future study is needed to determine whether subjects with higher levels of inflammation or immune activation derive greater cardiovascular benefit from statin therapy.